Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Synaptic neurodegeneration is thought to be an early event initiated by soluble β-amyloid (Aβ) aggregates that closely correlates with cognitive decline in Alzheimer disease (AD). Apolipoprotein ε4 (APOE4) is the most common genetic risk factor for both familial AD (FAD) and sporadic AD; it accelerates Aβ aggregation and selectively impairs glutamate receptor function and synaptic plasticity. However, its molecular mechanisms remain elusive and these synaptic deficits are difficult to monitor. AD- and APOE4-dependent plasma biomarkers have been proposed, but synapse-related plasma biomarkers are lacking. We evaluated neuronal pentraxin 1 (NP1), a potential CNS-derived plasma biomarker of excitatory synaptic pathology. NP1 is preferentially expressed in brain and involved in glutamate receptor internalization. NP1 is secreted presynaptically induced by Aβ oligomers, and implicated in excitatory synaptic and mitochondrial deficits. Levels of NP1 and its fragments were increased in a correlated fashion in both brain and plasma of 7–8 month-old E4FAD mice relative to E3FAD mice. NP1 was also found in exosome preparations and reduced by dietary DHA supplementation. Plasma NP1 was higher in E4FAD+ (APOE4+/+/FAD+/−) relative to E4FAD- (non-carrier; APOE4+/+/FAD−/−) mice, suggesting NP1 is modulated by Aβ expression. Finally, relative to normal elderly, plasma NP1 was also elevated in patients with mild cognitive impairment (MCI) and elevated further in the subset who progressed to early-stage AD. In those patients, there was a trend towards increased NP1 levels in APOE4 carriers relative to non-carriers. These findings indicate that NP1 may represent a potential synapse-derived plasma biomarker relevant to early alterations in excitatory synapses in MCI and early-stage AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3×
“EFAD transgenic (Tg) mice expressing 5 familial AD (FAD) mutations (Oakley et al., 2006) with human (h) APOE3 (E3FAD) or hAPOE4 (E4FAD), specifically 5xFAD+/-/APOE+/+, were used for this study, as well as EFAD- (non-carrier; APOE4+/+/FAD-/-) mice (Oakley et al., 2006).”
MethodInfluentialThe role of apolipoprotein E in Alzheimer's disease
Kim, J., Basak, J. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.06.026 · Cited by 1,661
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 3×
“Thus therapeutic strategies for AD should include synapse-protective interventions (Shankar et al., 2007) but synaptic degeneration cannot be directly monitored.”
BackgroundRegulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561
Zhuang, X., Xiang, X., Grizzle, W., Sun, D., Zhang, S., Axtell, R. C., Ju, S., Mu, J., Zhang, L., Steinman, L., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.164 · Cited by 1,356
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Reiman, E. M., Chen, K., Alexander, G. E., Caselli, R. J., Bandy, D., Osborne, D., Saunders, A. M., & Hardy, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2635903100 · Cited by 977
Exosomes are released by cultured cortical neurones
Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.003 · Cited by 896
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“While DHA treatment has not been shown to improve outcomes in mild-to-moderate AD dementia patients who carry an APOE4 allele (Quinn et al., 2010), it does appear to have beneficial effects on”
Begum, A. N., Jones, M. R., Lim, G. P., Morihara, T., Kim, P., Heath, D. D., Rock, C. L., Pruitt, M. A., Yang, F., Hudspeth, B., et al. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137455 · Cited by 604 · cited 1×
“…of age, these mice were implanted with intracerebroventricular (icv) pumps containing a solution of Aβ42 oligomers (released at 50 ng/hour) and human HDL (37 μg/h, Calbiochem, CA; for Aβ oligomer stabilization) or HDL alone as previously described (Frautschy et al., 2001, Begum et al., 2008).”
MethodSelf-citationPhenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Self-citationChen, Y., Durakoglugil, M. S., Xian, X., & Herz, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914984107 · Cited by 368
Tomic, J. L., Pensalfini, A., Head, E., & Glabe, C. G. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.05.024 · Cited by 336
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327 · cited 2×
“While some of this increased risk appears to be mediated through Aβ-associated mechanisms (Christensen et al., 2010, Hashimoto et al., 2012, Koffie et al., 2012), other APOE4-associated effects on dendritic spine density and morphology (Dumanis et al., 2009, Klein et al., 2010), glutamate receptor…”
BackgroundSinn, N., Milte, C. M., Street, S. J., Buckley, J. D., Coates, A. M., Petkov, J., & Howe, P. R. C. (2012) · British Journal of Nutrition · doi:10.1017/s0007114511004788 · Cited by 297
Xu, D., Hopf, C., Reddy, R., Cho, R. W., Guo, L., Lanahan, A., Petralia, R. S., Wenthold, R. J., O'Brien, R. J., & Worley, P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00463-x · Cited by 265 · cited 1×
“NP1 and NP2 form heterocomplexes that are required in vivo for the normal development of AMPAR-mediated transmission and function in developmental and activitydependent synaptic plasticity (Xu et al., 2003, Sia et al., 2007, Koch and Ullian, 2010).”
BackgroundApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo
Dumanis, S. B., Tesoriero, J. A., Babus, L. W., Nguyen, M. T., Trotter, J. H., Ladu, M. J., Weeber, E. J., Turner, R. S., Xu, B., Rebeck, G. W., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4026-09.2009 · Cited by 220
Self-citationGoetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219
Lee, L. K., Shahar, S., Chin, A.-V., & Yusoff, N. A. M. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2848-0 · Cited by 219
Sia, G.-M., Béïque, J.-C., Rumbaugh, G., Cho, R., Worley, P. F., & Huganir, R. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.06.020 · Cited by 201 · cited 1×
“NP1 interacts with the N-terminal domain of the AMPA receptor GluA4 subunit to mediate GluA4 synaptic recruitment (Sia et al., 2007).”
Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007000 · Cited by 187
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging
Jagust, W. J., Landau, S. M., & Initiative, F. T. A. D. N. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.3266-12.2012 · Cited by 162
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146 · cited 3×
“NP1 is enriched at excitatory synapses and functions closely associated with NP2 (Narp) and AMPARs.”
InfluentialMa, Q., Lim, G. P., Harris‐White, M. E., Yang, F., Ambegaokar, S. S., Ubeda, O. J., Glabe, C. G., Teter, B., Frautschy, S. A., & Cole, G. M. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20734 · Cited by 126 · cited 2×
“…the idea that soluble oligomeric Aβ (oAβ) represents the major Aβ toxic species that contributes to early synaptic and cognitive deficits in AD (Ma et al., 2006, Shankar et al., 2007, Gong and Iqbal, 2008, Tomic et al., 2009, Danysz and Parsons, 2012, Ma et al., 2013), involving ACCEPTED…”
BackgroundMethodSelf-citationCho, R. W., Park, J. M., Wolff, S. B. E., Xu, D., Hopf, C., Kim, J.-A., Reddy, R. C., Petralia, R. S., Perin, M. S., Linden, D. J., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.010 · Cited by 125
Accumulation of intraneuronal Aβ correlates with ApoE4 genotype
Christensen, D. Z., Schneider-Axmann, T., Lucassen, P. J., Bayer, T. A., & Wirths, O. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0666-1 · Cited by 120
Brinkmalm, G., Sjödin, S., Simonsen, A. H., Hasselbalch, S. G., Zetterberg, H., Brinkmalm, A., & Blennow, K. (2018) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201700131 · Cited by 111
Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking
Guntupalli, S., Widagdo, J., & Anggono, V. (2016) · Neural Plasticity · doi:10.1155/2016/3204519 · Cited by 110 · cited 2×
“In mature neurons, NP1 negatively regulates excitatory density and synaptic plasticity (Figueiro-Silva et al., 2015), a process known to be Aβ oligomer sensitive (Guntupalli et al., 2016).”
BackgroundAbad, M. A., Enguita, M., DeGregorio-Rocasolano, N., Ferrer, I., & Trullas, R. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0575-06.2006 · Cited by 102
Klein, R. C., Mace, B. E., Moore, S. D., & Sullivan, P. M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.027 · Cited by 67 · cited 1×
“associated synaptic dysfunction (Klein et al., 2010) may closely link to NP1 dysfunction.”
DeGregorio-Rocasolano, N., Gasull, T., & Trullas, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007967200 · Cited by 56
Neuronal Pentraxin 1 Negatively Regulates Excitatory Synapse Density and Synaptic Plasticity
Figueiro-Silva, J., Gruart, A., Clayton, K. B., Podlesniy, P., Abad, M. A., Gasull, X., Delgado-García, J. M., & Trullas, R. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2548-14.2015 · Cited by 53 · cited 2×
“In mature neurons, NP1 negatively regulates excitatory density and synaptic plasticity (Figueiro-Silva et al., 2015), a process”
Mechanisms of memory loss in Aβ and tau mouse models
Ashe, K. H. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330591 · Cited by 42
Clayton, K. B., Podlesniy, P., Figueiro-Silva, J., López-Doménech, G., Benitez, L., Enguita, M., Abad, M. A., Soriano, E., & Trullas, R. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.4604-11.2012 · Cited by 28 · cited 3×
“NP1 negatively regulates mitochondrial function, transport and caspase activation through (Clayton et al., 2012) and negatively regulates excitatory synapse density (Figueiro-Silva et al., 2015).”
Background
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“APOE mice • APOE4 is associated with increased NP1 levels [317] Plasma https://doi.”
BackgroundGómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94
Kovács, R. Á., Vadászi, H., Bulyáki, É., Török, G., Tóth, V., Mátyás, D., Kun, J., Hunyadi-Gulyás, É., Fedor, F. Z., Csincsi, Á., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599771 · Cited by 43
Metadata
- Authors
- Ma, Q.-L., Teng, E., Zuo, X., Jones, M., Teter, B., Zhao, E. Y., Zhu, C., Bilousova, T., Gylys, K. H., Apostolova, L. G., LaDu, M. J., Hossain, M. A., Frautschy, S. A., & Cole, G. M.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 114
- Pages
- 120-128
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2792619661
- Cited by
- 32
- References
- 34
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.